

VCBeat Health Contact Us

China Healthcare Select

Vertical Industries 

Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory

Home MediLink's YL201 Proposed for Breakthrough Therapy Designation in Refractory Pancreatic Cancer

MediLink's YL201 Proposed for Breakthrough Therapy Designation in Refractory Pancreatic Cancer

May 28, 2026 15:14 CST Updated 15:51

Share:

MediLink

Antibody-Drug Conjugates Developer

vcbeatglobal@vcbeat.net 

SERVICES

Partnership Development Market Entry Advisory Ecosystem Engagement Advisory

COMPANY

About VCBeat Why VCBeat Contact Us

CHANNELS

China Healthcare Select Insights MNC China Lens Events VB100 GMPC

MORE

PRIVACY VCBEAT CHINA

© 2025 VCBeat. All rights reserved.